title: Effect of alosetron on the pharmacokinetics of fluoxetine.
abstract: Lotronex (alosetron hydrochloride) is a 5-HT3 receptor antagonist indicated for the treatment of irritable bowel syndrome (IBS) in females whose predominant bowel habit is diarrhea. Alosetron is extensively metabolized by multiple cytochrome P450 (CYP) enzymes, including CYP2C9 and CYP3A4. Fluoxetine is an antidepressant that is administered as a racemic mixture of equipotent R- and S-enantiomers. Fluoxetine metabolism involves CYP2D6 and CYP2C9 in the formation of its major metabolite, norfluoxetine. This metabolite is also present as two enantiomers, of which only the S-enantiomer exhibits comparable antidepressant activity. This study was conducted to assess the potential for an effect of alosetron on the pharmacokinetics of fluoxetine. This was an open-label, two-period, nonrandomized, crossover study in 12 healthy female and male volunteers. The pharmacokinetics for both enantiomers of fluoxetine and norfluoxetine were examined following single oral doses of 20 mg fluoxetine, given alone and in combination with alosetron 1 mg twice daily for 15 days. The results showed small delays in peak concentration but no clinically significant effect of alosetron on the pharmacokinetics of S- and R-fluoxetine or S- and R-norfluoxetine. Coadministration of alosetron and fluoxetine was well tolerated by all subjects.
authors: Department of Clinical Pharmacology, Glaxo Wellcome Canada, Mississauga, Ontario.
authors: D L
authors: DL
authors: D'Souza
authors: D C
authors: DC
authors: Dimmitt
authors: D K
authors: DK
authors: Robbins
authors: J
authors: J
authors: Nezamis
authors: L
authors: L
authors: Simms
authors: K M
authors: KM
authors: Koch
mesh_terms: D000284:Administration, Oral; D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000493:pharmacokinetics*; D001682:Biological Availability; D002243:Carbolines / Q000008:administration & dosage / Q000494:pharmacology*; D003106:Colon / Q000187:drug effects; D003109:Colonic Diseases, Functional / Q000188:drug therapy*; D018592:Cross-Over Studies; D003577:Cytochrome P-450 Enzyme System / Q000235:genetics / Q000378:metabolism*; D004347:Drug Interactions; D005260:Female; D005473:Fluoxetine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives / Q000493:pharmacokinetics*; D005838:Genotype; D006207:Half-Life; D006801:Humans; D007527:Isoenzymes / Q000235:genetics / Q000378:metabolism*; D008297:Male; D008657:Metabolic Clearance Rate; D008875:Middle Aged; D012702:Serotonin Antagonists / Q000494:pharmacology*; D013997:Time Factors
chemical_list: D018687:Antidepressive Agents, Second-Generation; D002243:Carbolines; D007527:Isoenzymes; D012702:Serotonin Antagonists; D005473:Fluoxetine; C090840:alosetron; D003577:Cytochrome P-450 Enzyme System; C036139:norfluoxetine